BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the "AGM") was held at the Company's headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT). About SOPHiA GENETICS Investors Contact: Kellen Sanger IR@sophiagenetics.com The Company would like to thank all shareholders represen ...

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be ava ...

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of further ...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution ...

"At SOPHiA GENETICS we are committed to accelerating and expanding the use of precision medicine," said Ricardo Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. "Instituto Mário Penna is a staple within the cancer-care community in Brazil, and its implementation of the SOPHiA DDM™ Platform shows its commitment to advancing cancer care. We are confident that our AI-based platform will help Instituto Mário Penna generate fast, accurate, and meaningful insights to support researchers and clinic ...

"Precision medicine makes novel therapies for cancer treatment possible," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "The implementation of the SOPHiA DDM™ Platform will help Klinikum Klagenfurt am Wörthersee produce reliable insights from its testing while saving time and valuable resources." The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland, May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cl ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and IR Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO and COO Conference Call Participants Conor McNamara - RBC Capital Markets Yuko Mihara - Morgan Stanley Vivian Bais - BTIG Operator Good day everyone. My name is Jamie and I'll be your conference operator today. At this time, I'd like to welcome everyone to the SOPHiA GENETICS First Quarter 2024 Earnings Confer ...

:°: SOPHiA ·°·: GENETICS™ No offer to sell or buy Market and industry data © SOPHiA GENETICS 2024 3 4 © SOPHiA GENETICS 2024 For decades, health data has been produced in silos © SOPHiA GENETICS 2024 SOPHiA DDM™ is a decentralized analytics platform which computes © SOPHiA GENETICS 2024 $25B $15B Generating insights from multimodal data to help Clinicians with screening, early detection, diagnosis, therapy selection, and monitoring The decentralized, cloud-based analytics platform at the center of it all No ...

SOPHiA GENETICS SA (SOPH) closed the last trading session at $5.05, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.33 indicates a 65% upside potential.The average comprises three short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.53. While the lowest estimate indicates an increase of 38.6% from the current price leve ...

dated as of May 2, 2024 among SOPHiA GENETICS SA as Borrower, The Guarantors From Time To Time Party Hereto, as Guarantors, The Lenders From Time To Time Party Hereto, as Lenders, Execution Version Credit Agreement and Guaranty and Perceptive Credit Holdings IV, LP, as the Administrative Agent and as a Lender 4894-2985-1820 7040231 #98195096v26 Table of Contents Section Heading Page Schedules: | Schedule | 1 | — | Commitments and Warrant Shares | | --- | --- | --- | --- | | Schedule | 2 | — | Notice Address ...